the aid library

LIST OPTIONS

Filter

6713

Epidemiology and Challenges of Managing COPD in sub-Saharan Africa

Magitta, N.F.; Sciences, A. Acta Scientific Medical Sciences (2018) CC2

There is paucity of data on the burden and specific drivers operative in the pathogenesis of chronic obstructive pulmonary disease (COPD) in the African setting and populations. Lack of awareness and inadequate knowledge on the aetio-pathogenesis of the disease together with inadequate capacity for ... more

Download (158)

View PDF (207)

Guidelines for COVID-19 testing and quarantine of air travellers - Addendum to the Aviation Health Safety Protocol

European Centre for Disease Prevention and Control ECDC (2020) CC

This joint ECDC-European Union Aviation Safety Agency (EASA) document aims to support Member States in determining a coordinated approach to reduce the risks related to the movement of people by air within and between the EU/EEA countries and the UK in the context of the COVID-19 pandemic, noting th... more

Download (355)

View PDF (561)

Living Conditions among People with Activity Limitations in Zambia: A National Representative Study.

Arne H Eide & ME Loeb SINTEF Health Research (2006) C1

This research report provides results from the study on living conditions among people with disabilities in Zambia. Comparisons are made between individuals with and without disabilities and also between households with and without a disabled family member. Results obtained in Zambia are also compar... more

Download (273)

View PDF (261)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (172)

View PDF (221)

Rapport mondial 2020 : Agissons maintenant - Pour combattre les profondes inégalités et mettre fin aux pandémies
recommended

ONUSIDA (2020) C_WHO

Objectifs 2020 : des avancées disparates. Le rapport de l’ONUSIDA sur l’épidémie mondiale de sida fait état d’un échec accentué par la COVID-19. Depuis 2015, 3,5 millions d’infections au VIH et 820 000 morts supplémentaires liés au sida sont imputables à des objectifs non atteints. ... more

Download (167)

View PDF (180)

In all our Diversity 2015 Highlights

J. Bushee; R. Gustav; J.Hows; et al. GNP+ (Global Network of people living with HIV) (2016) C2

Download (159)

View PDF (219)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

External Link

Environmental Determinants of Cardiovascular Disease

Bhatnagar, A. Circulation Research (2018) CC

Many features of the environment have been found to exert an important influence on cardiovascular disease (CVD) risk, progression, and severity. Changes in the environment due to migration to different geographic locations, modifications in lifestyle choices, and shifts in social policies and cultu... more

Download (1375)

View PDF (1557)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (703)

View PDF (886)

Ghana National Health Insurance Scheme Improving Financial Sustainability Based on Expenditure Review

Huihui Wang, Nathaniel Otoo, and Lydia Dsane-Selby World Bank Group (2017) C1

Download (5685)

View PDF (1595)

Pharmaceutical management and prescribing pattern of antimalarial drugs in the public health facilities in Dar-es-Salaam, Tanzania

Richard Sebastian Silumbe (2011) C1

Master of Science in Pharmaceutical Management Dissertation

Download (776)

View PDF (1061)

Joint Government of the Repubic of Zambia and the United Nations Population Fund 2007 – 2010 Evaluation Report

Ministry of Finance and National Planning, Zambia (2010) C1

Download (524)

View PDF (570)

Epidemic meningitis surveillance in the African meningitis belt

World Health Organization WHO (2014) C_WHO

Download (574)

View PDF (977)

Tanzania: HIV Care and Treatment Plan 2003-2008

The William J. Clinton Foundation Ministry of Health, Tanzania (2003) C1

Download (792)

View PDF (1346)

National Strategic Framework for the Elimination of Obstetrics Fistula in Nigeria 2011-2015

Federal Ministry of Health, Nigeria (2012) C1

Download (435)

View PDF (885)

Key considerations: the context of North Kivu province, DRC

Social Science in Humanitarian Action: A Communication for Development Platform (2018) C1

This brief focuses specifically on the Grand Nord (Great North): the Beni and Lubero territories of northern North Kivu that are the epicentre of the outbreak. Further participatory enquiry should be undertaken with the affected populations, but given ongoing transmission, conveying key consideratio... more